Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Patholog Res Int. 2011;2011:216086. doi: 10.4061/2011/216086. Epub 2011 May 24.

Morphological analysis of CDC2 and glycogen synthase kinase 3β phosphorylation as markers of g2 → m transition in glioma.

Author information

  • 1Division of Neuropathology, Department of Pathology, University of California, San Francisco, 505 Parnassus Avenue, Moffit-Long Hospital, San Francisco, CA 94143, USA.

Abstract

G2 → M transition is a strategic target for glioma chemotherapy. Key players in G2 → M transition include CDC2 and glycogen synthase kinase 3β (GSK3β), which are highly regulated by posttranslational phosphorylation. This report is a morphological analysis of CDC2 and GSK3β phosphorylation using immunohistochemistry in gliomas with different biological properties. GBM showed a 2.8-fold and 5.6-fold increase in number of cells positive for pThr161CDC2 and a 4.2- and 6.9-fold increase in number of cells positive for pTyr15CDC2 relative to oligodendroglioma and ependymoma, respectively. Elevated labeling for inhibited phospho-CDC2 (pTyr15CDC) correlates with elevated levels of phosphorylated glycogen synthase kinase 3β (GSK3β). 71% of the GBM cases showed intermediate to high intensity staining for pSer9SGK3β 53% of oligodendroglioma, and 73% of ependymoma showed low intensity staining. CDC2 gene amplification correlates with increased survival in glioblastoma multiforme (GBM) and astrocytoma WHO grades II-III, but not in oligodendroglioma WHO grades II-III.

PMID:
21660227
[PubMed]
PMCID:
PMC3109336
Free PMC Article

Images from this publication.See all images (10)Free text

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk